- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Human Immunodeficiency Virus (HIV)
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 1425KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 348KB)
Cabotegravir/cabotegravir and rilpivirine – November 2021
Cabotegravir, cabotegravir and rilpivirine: Tablet containing cabotegravir 30 mg; Vocabria®; Pack containing 1 injection of cabotegravir 600 mg in 3 mL and 1 injection of rilpivirine 900 mg in 3 mL; Cabenuva®
Last updated
4 March 2022